Icares Medicus Inc Cash Flow Conversion Efficiency
Icares Medicus Inc cash flow conversion efficiency. Based on the latest financial reports, Icares Medicus Inc (6612) has a cash flow conversion efficiency ratio of -0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-5.69 Million ≈ $-179.36K USD) by net assets (NT$2.00 Billion ≈ $62.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Icares Medicus Inc (2017–2025)
Cash flow conversion efficiency of Icares Medicus Inc from 2017 to 2025. This chart illustrates how Icares Medicus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6612 stock price and chart for real-time trading data and today's change.
Icares Medicus Inc Cash Flow Conversion Ratio Explained
Icares Medicus Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Icares Medicus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icares Medicus Inc ranked by their cash flow conversion efficiency. Also see 6612 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Birla Cable Limited
NSE:BIRLACABLE
|
-0.018x |
|
Hwaseung Enterprise Co Ltd
KO:241590
|
0.018x |
|
ABL GROUP ASA NA NK-10
F:26Q
|
-0.048x |
|
Hispanotels Inversiones SOCIMI SA
MC:YHSP
|
0.092x |
|
Ryvu Therapeutics SA
WAR:RVU
|
-0.553x |
|
Southern Silver Exploration Corp.
V:SSV
|
-0.037x |
|
RTB Digital, Inc.
NASDAQ:RTB
|
-0.102x |
|
Impact Develop
RO:IMP
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Icares Medicus Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Icares Medicus Inc from 2017 to 2025. Review Icares Medicus Inc (6612) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.97 Billion ≈ $62.01 Million |
NT$-58.83 Million ≈ $-1.85 Million |
-0.030x | -8.59% |
| 2024-12-31 | NT$1.76 Billion ≈ $55.54 Million |
NT$-48.52 Million ≈ $-1.53 Million |
-0.028x | -78.13% |
| 2023-12-31 | NT$1.67 Billion ≈ $52.58 Million |
NT$-25.79 Million ≈ $-812.43K |
-0.015x | -111.24% |
| 2022-12-31 | NT$937.76 Million ≈ $29.54 Million |
NT$128.92 Million ≈ $4.06 Million |
0.137x | +192.61% |
| 2021-12-31 | NT$820.90 Million ≈ $25.86 Million |
NT$38.57 Million ≈ $1.22 Million |
0.047x | -53.76% |
| 2020-12-31 | NT$702.42 Million ≈ $22.13 Million |
NT$71.37 Million ≈ $2.25 Million |
0.102x | -25.26% |
| 2019-12-31 | NT$653.04 Million ≈ $20.57 Million |
NT$88.78 Million ≈ $2.80 Million |
0.136x | +22.87% |
| 2018-12-31 | NT$571.42 Million ≈ $18.00 Million |
NT$63.22 Million ≈ $1.99 Million |
0.111x | -18.11% |
| 2017-12-31 | NT$336.57 Million ≈ $10.60 Million |
NT$45.47 Million ≈ $1.43 Million |
0.135x | -- |
About Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataract… Read more